Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis

Grant Lewis, Patricia Hall, Nihal Eisa, David Deremer, Robin Dobbins, Mohamed El-Geneidy, Anand Jillella, Celalettin Ustun

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We evaluated the frequency of invasive fungal infections (IFI), the frequency of empirical antifungal use (EAFU), and the efficacy of fluconazole prophylaxis on IFI and EAFU after high-dose cytarabine (HiDAC) consolidations. Twenty-seven acute myelogenous leukemia patients in their first complete remission received 76 cycles of HiDAC (median cycle: n = 3). Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group). IFI (2 episodes) + EAFU (11 episodes) was observed in 13 of 76 cycles (17%); there was no difference between the fluconazole group and the control group (p = 0.469). Neutropenia duration was <13 days in 89% of the 76 cycles and was similar in the fluconazole and control groups (p = 0.845). Neutropenic fever was observed in 34 of the 76 cycles (45%) and was similar in the fluconazole group and the control group (p = 0.43). Although HiDAC cycle 1 was associated with a shorter neutropenia duration, there was no association between HiDAC cycle numbers and neutropenic fever or IFI + EAFU. HiDAC consolidations resulted in a high rate of neutropenic fever, the lack of an appreciable benefit from EAFU, and rare IFI. Most likely because of the low incidence of IFI, use of fluconazole or another antifungal is not warranted in this setting.

Original languageEnglish (US)
Pages (from-to)206-213
Number of pages8
JournalActa Haematologica
Volume124
Issue number4
DOIs
StatePublished - Dec 1 2010

Fingerprint

Fluconazole
Cytarabine
Acute Myeloid Leukemia
Control Groups
Fever
Neutropenia
Invasive Fungal Infections
Incidence

Keywords

  • Acute myelogenous leukemia
  • Antifungal prophylaxis
  • Fluconazole
  • High-dose cytarabine
  • Invasive fungal infections

ASJC Scopus subject areas

  • Hematology

Cite this

Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. / Lewis, Grant; Hall, Patricia; Eisa, Nihal; Deremer, David; Dobbins, Robin; El-Geneidy, Mohamed; Jillella, Anand; Ustun, Celalettin.

In: Acta Haematologica, Vol. 124, No. 4, 01.12.2010, p. 206-213.

Research output: Contribution to journalArticle

Lewis, Grant ; Hall, Patricia ; Eisa, Nihal ; Deremer, David ; Dobbins, Robin ; El-Geneidy, Mohamed ; Jillella, Anand ; Ustun, Celalettin. / Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. In: Acta Haematologica. 2010 ; Vol. 124, No. 4. pp. 206-213.
@article{570e96403abf487fb6cb2730ff14fdee,
title = "Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis",
abstract = "We evaluated the frequency of invasive fungal infections (IFI), the frequency of empirical antifungal use (EAFU), and the efficacy of fluconazole prophylaxis on IFI and EAFU after high-dose cytarabine (HiDAC) consolidations. Twenty-seven acute myelogenous leukemia patients in their first complete remission received 76 cycles of HiDAC (median cycle: n = 3). Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group). IFI (2 episodes) + EAFU (11 episodes) was observed in 13 of 76 cycles (17{\%}); there was no difference between the fluconazole group and the control group (p = 0.469). Neutropenia duration was <13 days in 89{\%} of the 76 cycles and was similar in the fluconazole and control groups (p = 0.845). Neutropenic fever was observed in 34 of the 76 cycles (45{\%}) and was similar in the fluconazole group and the control group (p = 0.43). Although HiDAC cycle 1 was associated with a shorter neutropenia duration, there was no association between HiDAC cycle numbers and neutropenic fever or IFI + EAFU. HiDAC consolidations resulted in a high rate of neutropenic fever, the lack of an appreciable benefit from EAFU, and rare IFI. Most likely because of the low incidence of IFI, use of fluconazole or another antifungal is not warranted in this setting.",
keywords = "Acute myelogenous leukemia, Antifungal prophylaxis, Fluconazole, High-dose cytarabine, Invasive fungal infections",
author = "Grant Lewis and Patricia Hall and Nihal Eisa and David Deremer and Robin Dobbins and Mohamed El-Geneidy and Anand Jillella and Celalettin Ustun",
year = "2010",
month = "12",
day = "1",
doi = "10.1159/000321504",
language = "English (US)",
volume = "124",
pages = "206--213",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis

AU - Lewis, Grant

AU - Hall, Patricia

AU - Eisa, Nihal

AU - Deremer, David

AU - Dobbins, Robin

AU - El-Geneidy, Mohamed

AU - Jillella, Anand

AU - Ustun, Celalettin

PY - 2010/12/1

Y1 - 2010/12/1

N2 - We evaluated the frequency of invasive fungal infections (IFI), the frequency of empirical antifungal use (EAFU), and the efficacy of fluconazole prophylaxis on IFI and EAFU after high-dose cytarabine (HiDAC) consolidations. Twenty-seven acute myelogenous leukemia patients in their first complete remission received 76 cycles of HiDAC (median cycle: n = 3). Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group). IFI (2 episodes) + EAFU (11 episodes) was observed in 13 of 76 cycles (17%); there was no difference between the fluconazole group and the control group (p = 0.469). Neutropenia duration was <13 days in 89% of the 76 cycles and was similar in the fluconazole and control groups (p = 0.845). Neutropenic fever was observed in 34 of the 76 cycles (45%) and was similar in the fluconazole group and the control group (p = 0.43). Although HiDAC cycle 1 was associated with a shorter neutropenia duration, there was no association between HiDAC cycle numbers and neutropenic fever or IFI + EAFU. HiDAC consolidations resulted in a high rate of neutropenic fever, the lack of an appreciable benefit from EAFU, and rare IFI. Most likely because of the low incidence of IFI, use of fluconazole or another antifungal is not warranted in this setting.

AB - We evaluated the frequency of invasive fungal infections (IFI), the frequency of empirical antifungal use (EAFU), and the efficacy of fluconazole prophylaxis on IFI and EAFU after high-dose cytarabine (HiDAC) consolidations. Twenty-seven acute myelogenous leukemia patients in their first complete remission received 76 cycles of HiDAC (median cycle: n = 3). Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group). IFI (2 episodes) + EAFU (11 episodes) was observed in 13 of 76 cycles (17%); there was no difference between the fluconazole group and the control group (p = 0.469). Neutropenia duration was <13 days in 89% of the 76 cycles and was similar in the fluconazole and control groups (p = 0.845). Neutropenic fever was observed in 34 of the 76 cycles (45%) and was similar in the fluconazole group and the control group (p = 0.43). Although HiDAC cycle 1 was associated with a shorter neutropenia duration, there was no association between HiDAC cycle numbers and neutropenic fever or IFI + EAFU. HiDAC consolidations resulted in a high rate of neutropenic fever, the lack of an appreciable benefit from EAFU, and rare IFI. Most likely because of the low incidence of IFI, use of fluconazole or another antifungal is not warranted in this setting.

KW - Acute myelogenous leukemia

KW - Antifungal prophylaxis

KW - Fluconazole

KW - High-dose cytarabine

KW - Invasive fungal infections

UR - http://www.scopus.com/inward/record.url?scp=78149344647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149344647&partnerID=8YFLogxK

U2 - 10.1159/000321504

DO - 10.1159/000321504

M3 - Article

C2 - 21071929

AN - SCOPUS:78149344647

VL - 124

SP - 206

EP - 213

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 4

ER -